Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2019 May;14(5):876-889.
doi: 10.1016/j.jtho.2019.01.020. Epub 2019 Feb 5.

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Badi El Osta  1 , Madhusmita Behera  1 , Sungjin Kim  2 , Lynne D Berry  3 , Gabriel Sica  4 , Rathi N Pillai  1 , Taofeek K Owonikoko  1 , Mark G Kris  5 , Bruce E Johnson  6 , David J Kwiatkowski  6 , Lynette M Sholl  6 , Dara L Aisner  7 , Paul A Bunn  8 , Fadlo R Khuri  1 , Suresh S Ramalingam  9
Affiliations
Multicenter Study

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

Badi El Osta et al. J Thorac Oncol. 2019 May.

Abstract

Introduction: Mutations in the KRAS gene are the most common driver oncogenes present in lung adenocarcinomas. We analyzed the largest multi-institutional database available containing patients with metastatic KRAS-mutant lung adenocarcinomas.

Methods: The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional collaboration to study the genomic characteristics of lung adenocarcinomas, treat them with genomically directed therapeutic approaches, and assess their outcomes. Since its inception in 2009, the LCMC has enrolled more than 1900 patients and has performed pretreatment, multiplexed, molecular characterization along with collecting clinical data. We evaluated the characteristics of patients with KRAS mutation in the LCMC and the association with overall survival.

Results: Data from 1655 patients with metastatic lung adenocarcinomas were analyzed. Four hundred fifty (27%) patients had a KRAS mutation, 58% were female, 93% were smokers, and there was a median age of 65 years. Main KRAS subtypes were: G12C 39%; and G12D and G12V at 18% each. Among patients with KRAS mutation, G12D had a higher proportion of never-smokers (22%, p < 0.001). Patients with KRAS-mutant tumors had a trend toward shorter median survival compared to all others in the series (1.96 versus 2.22; P = 0.08) and lower 2-year survival rate (49% [95% confidence interval: 44%-54%] and 55% [95% confidence interval: 52%-58%], respectively).

Conclusions: In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to one-third of them had another oncogenic driver. Patients with both KRAS and STK11 mutations had a significantly inferior clinical outcome.

Keywords: KRAS mutation; LKB1 mutation; Lung Cancer Molecular Consortium; Lung adenocarcinomas; Precision oncology; STK11 mutation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier estimates for KRAS mutant patients with lung adenocarcinomas with and without co-mutation.
Figure 2.
Figure 2.
Kaplan-Meier estimates for KRAS mutant patients with lung adenocarcinomas stratified by main 3 subtypes of KRAS mutation.
Figure 3.
Figure 3.
Kaplan-Meier estimates for KRAS mutant patients with lung adenocarcinomas stratified by codon of KRAS mutation.
Figure 4.
Figure 4.
Kaplan-Meier estimates for patients with lung adenocarcinomas stratified by molecular status.
Figure 5.
Figure 5.
Kaplan-Meier estimates for patients with lung adenocarcinomas stratified by KRAS and STK11 molecular status.
See this image and copyright information in PMC

References

    1. Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 2016;48:607–616. - PMC - PubMed
    1. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239–246. - PubMed
    1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385–2394. - PubMed
    1. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963–1971. - PMC - PubMed
    1. Planchard D, Besse B, Groen HJ, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 2016;17:984–993. - PMC - PubMed

Publication types

Substances